Gossamer Bio, Inc.
GOSS
$1.12
-$0.1282-10.26%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -1.07% | -90.11% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -1.07% | -90.11% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -1.07% | -90.11% | |||
| SG&A Expenses | 10.50% | -1.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.86% | -0.81% | |||
| Operating Income | -6.51% | -165.12% | |||
| Income Before Tax | -10.97% | -159.51% | |||
| Income Tax Expenses | -112.90% | -125.52% | |||
| Earnings from Continuing Operations | -7.23% | -162.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.23% | -162.57% | |||
| EBIT | -6.51% | -165.12% | |||
| EBITDA | -6.87% | -164.40% | |||
| EPS Basic | -114.18% | -162.55% | |||
| Normalized Basic EPS | -203.29% | -159.47% | |||
| EPS Diluted | -114.18% | -162.75% | |||
| Normalized Diluted EPS | -203.29% | -162.73% | |||
| Average Basic Shares Outstanding | 0.11% | 0.06% | |||
| Average Diluted Shares Outstanding | 0.11% | -5.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||